Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients

29 Apr 2025

Abstract excerpt

BACKGROUNDTebentafusp is the first T cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T cells toward gp100-expressing target cells, frequently inducing skin-related early adverse events.METHODSThis study investigated immunological and cellular responses using single-cell and spatial analysis of skin biopsies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Nanoplatforms for cancer theranostics
Share to Ocular Oncology and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40311102
DOI: 10.1172/jci181464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patientsPMID 40311102Read ↗

Ensuring equity in the era of HLA-restricted cancer therapeuticsSemantic proximity Read ↗

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.Semantic proximity Read ↗

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancerSemantic proximity Read ↗

Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastasesSemantic proximity Read ↗

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.Semantic proximity Read ↗

Advancements and Challenges in Personalized Therapy for BRAF-Mutant Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.Semantic proximity Read ↗

A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in MelanomaSemantic proximity Read ↗

Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.Semantic proximity Read ↗

Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma.Semantic proximity Read ↗

A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.